More significantly, WntSI effectively overcame acquired resistance to EGFR‐TKIs resulting from MET amplification in both cell line‐derived and patient‐derived tumor xenograft mouse models, while demonstrating exceptional biosecurity. Here, MET is linked to neoplasm.